Cargando…

Metabolic Profiling of Bladder Cancer Patients’ Serum Reveals Their Sensitivity to Neoadjuvant Chemotherapy

Numerous patients with muscle-invasive bladder cancer develop low responsiveness to cisplatin. Our purpose was to explore differential metabolites derived from serum in bladder cancer patients treated with neoadjuvant chemotherapy (NAC). Data of patients diagnosed with cT2-4aNxM0 was collected. Bloo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuang, Juntao, Yang, Xiao, Zheng, Qi, Li, Kai, Cai, Lingkai, Yu, Hao, Lv, Jiancheng, Bai, Kexin, Cao, Qiang, Li, Pengchao, Yang, Haiwei, Wang, Junsong, Lu, Qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229374/ https://www.ncbi.nlm.nih.gov/pubmed/35736490 http://dx.doi.org/10.3390/metabo12060558

Ejemplares similares

N6-methyladenosine-related single-nucleotide polymorphism analyses identify oncogene RNFT2 in bladder cancer
por: Lv, Jiancheng, et al.
Publicado: (2022)

HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1/PKM2 pathway
por: Lv, Jiancheng, et al.
Publicado: (2023)

Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade
por: Lv, Jiancheng, et al.
Publicado: (2023)

Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity
por: Yang, Xiao, et al.
Publicado: (2022)

The application value of multi-parameter cystoscope in improving the accuracy of preoperative bladder cancer grading
por: Wu, Qikai, et al.
Publicado: (2022)

Clinical significance, tumor immune landscape and immunotherapy responses of ADAR in pan-cancer and its association with proliferation and metastasis of bladder cancer
por: Yu, Hao, et al.
Publicado: (2023)

Robot-Assisted Totally Intracorporeal Resection of Cutaneous Ureterostomy Tumor and Ileal Conduit Surgery: A Rare Case Report
por: Cai, Lingkai, et al.
Publicado: (2022)

Bladder cancer-derived exosomal KRT6B promotes invasion and metastasis by inducing EMT and regulating the immune microenvironment
por: Song, Qiang, et al.
Publicado: (2022)

Identification of the circRNA-miRNA-mRNA Regulatory Network in Bladder Cancer by Bioinformatics Analysis
por: Lv, Jiancheng, et al.
Publicado: (2021)

External validation of Pentafecta in patients undergoing laparoscopic radical cystectomy: results from a high-volume center
por: Li, Kai, et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on bladder cancer patients: a multicenter real-world study
por: Wei, Yong, et al.
Publicado: (2023)

CircFAM114A2 Promotes Cisplatin Sensitivity via miR-222-3p/P27 and miR-146a-5p/P21 Cascades in Urothelial Carcinoma
por: Lv, Jiancheng, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade
por: Luo, Hao, et al.
Publicado: (2022)

Efficacy of immunonutritional supplement after neoadjuvant chemotherapy in patients with esophageal cancer
por: Luo, Chao, et al.
Publicado: (2022)

Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression
por: Yang, Chengdi, et al.
Publicado: (2018)

Neoadjuvant Chemotherapy in Invasive Bladder Cancer
por: Oliver, R.T.D.
Publicado: (1991)

Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR‐1270 inhibition
por: Yuan, Wenbo, et al.
Publicado: (2019)

Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2
por: Wang, Xiao-Xiao, et al.
Publicado: (2018)

Targeting protein kinase CK2 suppresses bladder cancer cell survival via the glucose metabolic pathway
por: Zhang, Xiaolei, et al.
Publicado: (2016)

ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2α-Mediated Glycolysis
por: Yu, Hao, et al.
Publicado: (2020)

An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer
por: Xylinas, Evanguelos, et al.
Publicado: (2016)

Role of MicroRNA-124 as a Prognostic Factor in Multiple Neoplasms: A Meta-Analysis
por: Zhou, Zijian, et al.
Publicado: (2019)

Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction
por: Li, Shoumiao, et al.
Publicado: (2017)

Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy
por: Sui, Wilson, et al.
Publicado: (2017)

Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience
por: Yu, Bin, et al.
Publicado: (2015)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report
por: Prelaj, Arsela, et al.
Publicado: (2016)

Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
por: Sherif, Amir, et al.
Publicado: (2018)

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer
por: Carvalho, Filipe LF., et al.
Publicado: (2020)

The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer
por: Sun, Juan, et al.
Publicado: (2021)

FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer
por: Zhang, Yang, et al.
Publicado: (2022)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
por: Yang, Zhao, et al.
Publicado: (2021)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

AB102. Functional promoter-94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population
por: Li, Pengchao, et al.
Publicado: (2014)

Adjuvant chemotherapy in patients with locally advanced bladder cancer after neoadjuvant chemotherapy and radical cystectomy: a systematic review and pooled analysis
por: Cai, Zhiyong, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
por: Shi, Hongzhe, et al.
Publicado: (2021)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Miyagi, Hiroko, et al.
Publicado: (2022)

Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel
por: Li, Qian, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b8q294sceilnj4guolft5hfntr